Huawei has positioned its new Watch Fit 5 Pro as a health-monitoring device rather than a simple fitness band, introducing a diabetes-risk assessment — a first for the FIT line — alongside ECG recording, arrhythmia analysis and arterial-stiffness checks.
The headline addition is what Huawei calls a diabetes risk study. Using the watch’s built-in optical sensors, the device continuously gathers vital-sign data — including sleep and resting metrics — over a period of three to 14 days, then analyses the readings to estimate a user’s diabetes risk level. The company notes that sustained abnormal blood-sugar levels can affect the behaviour and elasticity of blood vessels, the kind of subtle change the watch is designed to detect.
Huawei is careful to frame the feature as a screening aid rather than a diagnostic tool. The watch returns a risk-level assessment, not a medical diagnosis, and the company advises users flagged as at risk to consult a healthcare professional. The value, it argues, lies in surfacing potential warning signs during the asymptomatic stage, when lifestyle changes can make the most difference.
On the cardiovascular side, the FIT 5 Pro extends the heart-health tools Huawei has built into recent watches. Pulse-wave arrhythmia analysis, powered by a PPG sensor, monitors heart rhythm during normal wear to flag possible atrial fibrillation or premature beats, while a single-lead ECG function lets users capture a reading during symptoms. A separate check estimates arterial stiffness in about 30 seconds.
The wearable also adds an ovulation-prediction feature that uses a body-temperature sensor to track the small overnight shifts in wrist temperature associated with the menstrual cycle, and an upgraded emotional-health tool the company says can now distinguish 12 emotional states.
The launch reflects a broader industry shift, as smartwatch makers move beyond step counting toward preventive health screening. Rivals including Apple and Samsung have added ECG and other cardiac features to their wearables, and regulators in several markets have begun scrutinising how such consumer tools are marketed relative to certified medical devices.
For Huawei, packing this many health features into a mid-range wearable is also a competitive lever, particularly in markets such as the Middle East where the brand retains a strong following. As with every device in the category, the caveat is unchanged: a watch can prompt earlier attention, but it cannot replace a clinician.
